Terence Gade

Has grant

PI

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Hyperpolarized MR Imaging for Early Detection and Treatment Response Assessment of Post-MI Adverse Remodeling

Open Date: 2025-04-01

Close Date: 2028-03-31

Articles (12)

Year:

2026

Background and aims Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies to identify genomic alterations that could lead to actionable drug targets and biomarkers. Methods Optical genome mapping (OGM) and whole exome sequencing (WES) were performed on 70 liver metastases of neuroendocrine tumors from multiple anatomical primary sites. PacBio Iso-Seq long read sequencing and western blotting was used to confirm fusion gene expression. Findings were validated by rtPCR and western blotting on a separate cohort of 17 resection specimens from 14 pancreatic NET cases. Results Somatic variant calling from OGM data detected recurrent fusions involving TBL1X ( PSIP1::TBL1X ) and BEND2 ( CHD7::BEND2 and NEO1::BEND2 ) in pancreatic neuroendocrine tumors (pNETs). BEND2 fusions were associated with high grade tumors, as previously described. The novel PSIP1::TBL1X fusion was confirmed to result in fusion transcript expression by both long-read sequencing and nested rtPCR. Presence of the PSIP1::TBL1X fusion transcript was also confirmed in a second cohort of pNET resection specimens and fusion protein expression was established by western blotting. Both TBL1X and BEND2 fusions are mutually exclusive with ATRX/DAXX mutations. Conclusion This study underscores the importance of structural variants, including fusion genes as both prognostic biomarkers and potential therapeutic targets, especially in ATRX/DAXX negative pNETs. BEND2 fusion positivity may be a clinically useful biomarker for aggressive disease. As all TBL1X fusion isoforms contain the entire TBL1X coding sequence, TBL1X inhibition could be explored as a novel treatment for TBL1X fusion positive pNETs.

Year:

2025

Mass Spectrometry Imaging (MSI) is an emergent tool for analyzing spatial molecular distributions, yet data complexity often hinders effective analysis. MSI.EAGLE, an open-source R-Shiny application, makes analysis accessible for non-specialists by integrating advanced tools in a user-friendly interface. The workflow leverages tools from the Cardinal MSI package, with enhanced phenotyping, segmentation, statistical analysis and visualization. The application addresses a gap in spatial biology research by empowering a broader scientific community.

Year:

2025

Year:

2024

PURPOSE To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). METHODS ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations. RESULTS Ten new RCTs met the inclusion criteria and were added to the evidence base. RECOMMENDATIONS Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1. Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line. Following first-line treatment with atezo + bev, second-line therapy with a tyrosine kinase inhibitor (TKI), ramucirumab (for patients with alpha-fetoprotein [AFP] ≥400 ng/mL), durva + treme, or nivolumab + ipilimumab (nivo + ipi) may be recommended for appropriate candidates. Following first-line therapy with durva + treme, second-line therapy with a TKI is recommended. Following first-line treatment with sorafenib or lenvatinib, second-line therapy options include cabozantinib, regorafenib for patients who previously tolerated sorafenib, ramucirumab (AFP ≥400 ng/mL), nivo + ipi, or durvalumab; atezo + bev or durva + treme may be considered for patients who did not have access to these therapies in the first-line setting, and do not have contraindications. Pembrolizumab or nivolumab are also options for appropriate patients following sorafenib or lenvatinib. Third-line therapy may be considered in Child-Pugh class A patients with good PS, using one of the agents listed previously that has a nonidentical mechanism of action with previously received therapy. A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Year:

2024

Supplementary Figure 4: In-Vivo treatment schedule of injections and imaging. After i.p. injection of saline or T-cells, tumors were injected with saline, scGPC3/CD3, or the GPC3/CD3 bispecific antibody every 12 hours for a total of five injections. This serial injection sequence was repeated on the fourth day following the first injection. Mice were euthanized on day 14 with tumor tissues preserved for histology.

Year:

2024

Supplementary Figure S1: Expression and Purification of TRAB Recombinant Protein. Synthesized TRAB gene fragments (IDT DNA, Coralville, IA), as specified in figure above (A), were inserted into a pTXB1 (New England Biolabs) vector using standard restriction enzyme based cloning techniques. Insertion of the TRAB sequence was verified by DNA sequencing using the T7 promoter as the sequencing primer. The TRAB-pTXB1 plasmids were then transformed into a competent E coli expression cell line (Origami 2 Cells, Novagen). Bacterial cell cultures were initially grown overnight in an air shaker (225 rpm) at 37°C in 3 mL of lysogeny broth (LB) media, eventually inoculated into scaled up 1 L LB media containing 50 mg/L of ampicillin. At optical density (OD) 600 nm = 0.6, Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures were allowed to express for 2 h at 37°C. Bacterial cultures were centrifugally pelleted at 10,000 g for 30 min, resuspended in 5 mL of column buffer (20 mM Na-HEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM phenylmethylsulfonyl fluoride. Cells were lysed by pulse sonication on ice. Cell lysate was centrifuged at 15,000 g for 30 min at 4°C. Supernatant was then loaded and incubated in Poly-Prep chromatography column (Bio-Rad, Hercules, CA) packed with Talon metal affinity resin (Clontech, Mountain View, CA). Supernatant was then allowed to pass through the column and resin beads were washed with multiple rounds of column buffer (0.1 M Tris-HCl, pH 8.5). Bound and washed TRAB protein (sequence shown in panel B) was then released from metal resin via the addition of 200 mM imidazole-containing elution buffer. Purification and concentration of the final product was performed using a 3 kDa molecular weight cutoff (MWCO) filter (Amicon Ultra, Milipore, Temecula, CA). The final product was analyzed on SDS-PAGE protein gel (Figure 2), with confirmation of the protein band at the expected molecular weight.

Year:

2024

Supplementary Figure S3: GPC3-specific targeting peptide has a similar binding pattern to HCC samples compared to immunostaining with GPC3 antibody. (A-D) Representative contiguous slides from HCC samples stained with GPC3 antibody (A, B) and GPC3-specific peptide (C, D) demonstrate similar staining patterns. HCC, hepatocellular carcinoma.

Year:

2024

Supplementary Figure S2: GPC3 expression in HCC samples and normal adjacent liver. Sample images from immunostaining showing nearly absent GPC3 expression in normal adjacent liver (n=41) (A, B) and high GPC3 expression in HCC tumors (n=47) (C,D). 79% of the tumors (79%) stained strongly positive for GPC3 expression (Grade 3 and 4) (E). Within normal adjacent liver samples only 2 (5%) had grade 3/4 GPC3 expression compared to 79% among HCC tumor samples (F).

Year:

2024

Glypican-3 (GPC3) is a proteoglycan with high sensitivity and specificity for hepatocellular carcinoma (HCC). We describe the integrated development and validation of a GPC3-targeting optical imaging probe and T cell–redirecting antibody (TRAB) as a theranostic strategy for the detection and treatment of HCC. A novel TRAB targeting GPC3 on HCC tumor cells and the CD3 T-cell receptor as well as a distinct GPC3-specific optical imaging probe were developed from a short peptide. The efficacy of GPC3/CD3 TRAB was evaluated in vitro using IFNγ release and calcein-AM assays. Patient-derived xenografts were used to assess the in vivo efficacy of GPC3/CD3 TRAB and the GPC3 imaging probe for the detection of GPC3+ HCC. GPC3/CD3 TRAB caused a dose-dependent escalation in IFNγ release from inactive peripheral blood T cells ( P = 0.001) and higher tumor-cell lysis ( P = 0.01) compared with controls in vitro . Intratumorally injected GPC3/CD3 TRAB resulted in significant prolongation of tumor doubling time in the GPC3+ tumors, with an associated reduction of tumor fluorescent signal from the HiLyte 488–conjugated GPC3-specific peptide on optical imaging. These data demonstrate that HCC cell targeting using a GPC3/CD3 TRAB derived from a small peptide enabled effective T-cell activation and induction of a cytotoxic response toward GPC3+ HCC tumor cells both in vitro and in vivo. GPC3-specific optical imaging enabled the detection of the GPC3+ HCC cells and noninvasive monitoring of tumor response to adoptive immunotherapy. The integrated development of a targeted therapeutic and molecular imaging probe provides a promising paradigm for the development of cancer theranostics.

Year:

2024

Year:

2024

Year:

2023

Collaborators (12)

Richard Shlansky-Goldberg

Professor

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Garret A. FitzGerald

University of Pennsylvania

UNITED STATES
View details

Sunil Krishnan

Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

David Cormode

Professor

University of Pennsylvania

UNITED STATES
View details

Kelley Weinfurtner

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

S. Cheenu Kappadath

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John D. Gordan

University of California

UNITED STATES
View details

Daniel Ackerman

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Bryson Katona

Assistant Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Andrew Tsourkas

Professor

University of Pennsylvania

UNITED STATES
View details

George McClung

Staff Scientist

University of Pennsylvania

UNITED STATES
View details

David Kaplan

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details